Combined traumatic brain injury (TBI) and hemorrhagic shock (HS) remains a leading
cause of preventable death worldwide. Mesenchymal stem cell-derived exosomes have …

BACKGROUND Administration of human mesenchymal stem cell (MSC)–derived exosomes
can enhance neurorestoration in models of traumatic brain injury (TBI) and hemorrhagic …

BACKGROUND Combined traumatic brain injury (TBI) and hemorrhagic shock (HS) is highly
lethal. In a nonsurvival model of TBI+ HS, addition of high-dose valproic acid (VPA)(300 mg/…

BACKGROUND We have previously shown that treatment with valproic acid (VPA) decreases
brain lesion size in swine models of traumatic brain injury (TBI) and controlled hemorrhage…

BACKGROUND Early single-dose treatment with human mesenchymal stem cell–derived
exosomes promotes neuroprotection and promotes blood-brain barrier integrity in models of …

BACKGROUND Hemorrhage is a leading cause of mortality in trauma. Resuscitative endovascular
balloon occlusion of the aorta (REBOA) can control hemorrhage, but distal ischemia, …

BACKGROUND The use of partial resuscitative endovascular balloon occlusion of the aorta
(pREBOA) in combined hemorrhagic shock (HS) and traumatic brain injury (TBI) has not …

We have shown previously that fresh frozen plasma (FFP) and lyophilized plasma (LP) decrease
brain lesion size and improve neurological recovery in a swine model of traumatic brain …

BACKGROUND Valproic acid (VPA) is a histone deacetylase inhibitor that improves outcomes
in large animal models of trauma. However, its protective mechanism of action is not …

BACKGROUND The clinical usage of the resuscitative endovascular balloon occlusion of
the aorta (REBOA) is limited by distal ischemia resulting from complete aortic occlusion. We …